UNIGE document Scientific Article
previous document  unige:78440  next document
add to browser collection

Leucémie lymphoïde chronique : quand débuter le traitement ?

Published in Revue médicale suisse. 2013, vol. 9, no. 402, p. 1870-1874
Abstract This paper reviews the literature to propose guidelines for managing patients with early-intermediate stage chronic lymphocytic leukemia (CLL). Clinical and biological parameters are sufficient to identify a cohort of patients with high-risk CLL at diagnosis who will have disease progression: anemia (Hb < 100 g/l) or thrombocytopenia (platelets < 100 G/l), bone marrow infiltration (> 30% lymphocytes), a rapid doubling time (less than 6 months) or lymphocytes above 300 g/L, splenomegaly and massive lymphadenopathy, systemic symptoms, uncontrolled autoimmune complications. Patients without those characteristics have low-risk CLL. In the absence of evidence of survival benefit in low-risk CLL, there is no indication for treatment and patients should be followed up by physical examination and complete blood count once or twice a year.
Keywords Blood Cell Count/methodsDisease ProgressionHumansLeukemia, Lymphocytic, Chronic, B-Cell/diagnosis/pathology/therapyNeoplasm StagingPractice Guidelines as TopicRiskSurvival AnalysisTime Factors
PMID: 24298709
Full text
Article (Published version) (521 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Groupe Perrier Arnaud (Médecine interne générale, de réhabilitation et de gériatrie) (585)
(ISO format)
BLASER, Samuel, STIRNEMANN, Jérôme, NAGY, Monika. Leucémie lymphoïde chronique : quand débuter le traitement ?. In: Revue médicale suisse, 2013, vol. 9, n° 402, p. 1870-1874. https://archive-ouverte.unige.ch/unige:78440

521 hits

1 download


Deposited on : 2015-12-09

Export document
Format :
Citation style :